A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2014
Price : $35 *
At a glance
- Drugs Atabecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 11 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Jul 2014 New trial record